Family medicine

Anemia

INESSS PMN No 888030 (September 2026) is Québec IV iron in adults. Clinic doses, infusion rates, and coverage codes live in the PMN and OIPI — open those.

Diagnose

  • INESSS Institut national d'excellence en santé et services sociaux
DecisionGuideline
Who
Adults ≥18 y with iron deficiency per PMN ferritin / TSAT.General ferritin <30 mcg/L. Other cutoffs for inflammation, CKD, HFrEF, ESA-cancer — open the PMN table.
  • Iron deficiency without anemia has limited support except named PMN indications.

INESSS opens in a new tab

Treat

Open the INESSS PMN and OIPI for milligram schedules, dilution volumes, infusion rates, and RAMQ codes.

  • INESSS Institut national d'excellence en santé et services sociaux
DecisionGuideline
Who / when IV iron
Prefer IV when
Prefer IV when oral iron is ineffective or intolerant, and in the named PMN situations. Open the full list.
  • Prefer IV for anemia with iron deficiency.
  • Severe anemia symptoms
  • Anticipated poor oral absorption
  • Chronic blood loss
  • Chronic hemodialysis
  • Severe anemia in pregnancy (Hb <70 g/L)
  • Named peri-op / late-pregnancy bleed-risk situations — open the PMN list.

INESSS opens in a new tab

Contraindications
Prior anaphylaxis to one IV iron formulation is a contraindication to that formulation, not to the whole protocol.
  • Pregnancy and breastfeeding are not absolute contraindications;
  • weigh risks and benefits (few data in the first trimester).
  • Active systemic infection: consider temporarily holding IV iron if not urgent.

INESSS opens in a new tab

Products (September 2026)
Ferric carboxymaltose
September 2026 PMN adds ferric carboxymaltose (carboxymaltose ferrique), on the RAMQ list since November 2025 per the INESSS publication, alongside other parenteral options named in the protocol — open the live table.
  • The update also clarifies prevention for persons with risk factors — open the PMN.

INESSS fer IV repertoire opens in a new tabINESSS opens in a new tab

Hypophosphatemia
Hypophosphatemia risk may increase with repeated carboxymaltose doses.Open the PMN.

INESSS opens in a new tab

Test dose
No routine test dose or premedication is recommended for the parenteral preparations in the protocol.Administer where anaphylaxis can be managed (epinephrine available).

INESSS opens in a new tab

Posology
Open the PMN and OIPI for posology, infusion rates, and maximum per dose.

INESSS opens in a new tabINESSS OIPI fer IV opens in a new tab

Infusion reactions
Distinguish
During infusion, distinguish anaphylaxis vs Fishbane vs isolated symptoms.Fishbane is non-allergic, variable, usually early, and without strong anaphylaxis signs. Follow the PMN section 7 decision algorithm and the OIPI. Do not reprint the tree.

INESSS opens in a new tabINESSS OIPI fer IV opens in a new tab

Antihistamines
Antihistamines should not be given for Fishbane reactions (may worsen) — PMN algorithm note.

INESSS opens in a new tab

Next dose
After Fishbane or isolated symptoms without anaphylaxis, the next administration may proceed with protocol adjustments (for example lower dose or slower rate) as in the algorithm — open the PDF.

INESSS opens in a new tabINESSS OIPI fer IV opens in a new tab

Follow-up

  • INESSS Institut national d'excellence en santé et services sociaux
DecisionGuideline
Labs
Lab follow-up modalities are in the PMN (ferritin / TSAT / Hb timing).Open that section.

INESSS opens in a new tab

Reviewed 28 September 2026 against the official sources below.

Sources